Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Max-40279-01 in Advanced Colorectal Cancer
NCT05130021Phase 2Unknown
- Sponsor
- Guangzhou Zaiji Medical Technology
- Start
- Jan 2022
- Primary completion
- May 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised trial of nefextinib in colorectal cancer (CRC) (4 arms), sponsored by Guangzhou Zaiji Medical Technology. Primary endpoints: Disease Control Rate at 6 months and Progression-Free Survival at 6 months. Status: unknown.
02
Drugs
nefextinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05130021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05130021.